Bio-Techne to push further into clinical diagnostic market with Cliniqa acquisition

California-based Cliniqa’s controls and reagents are used for diagnostic tests for cardiac disease, diabetes, cancer, immunological disorders, therapeutic drug monitoring, urine analysis and toxicology. 

With over 165 510(k) clearances issued by the US FDA, Cliniqa has a management team that brings significant clinical diagnostics and regulatory experience to Bio-Techne. The leadership team will remain in place following the closure of the acquisition, which is expected to occur around July 1.

Charles R. Kummeth, President and CEO of Bio-Techne, said, "The addition of Cliniqa adds important capabilities to Bio-Techne as we continue to solidify our market presence and expand our business into key adjacent markets, such as immunodiagnostics.  This acquisition also strengthens and expands our Clinical Controls Division, allowing us to offer our customers a broader spectrum of products and services to serve their needs​."